Pfizer price target raised to $28 from $27 at Wells Fargo

Wells Fargo raised the firm’s price target on Pfizer (PFE) to $28 from $27 and keeps an Equal Weight rating on the shares. With better-than-expected EPS guidance largely driven by expense management and better COVID outlook, the firm still thinks Pfizer has a topline problem as it enters an loss of exclusivity period through the end of the decade.